After today's market close, the pharmacy benefit management company reported adjusted earnings of $1.74 per diluted share, beating analysts' estimates by a penny per share.
Revenue of $25.41 billion missed Wall Street's projections of $25.51 billion.
In the fourth quarter, Express Scripts sees adjusted earnings per share of $1.84 to $1.90 compared to Wall Street's forecasts of $1.85 per share.
For the full year, the St. Louis-based company expects adjusted earnings per share between $6.36 and $6.42 vs. its prior view of $6.33 per share to $6.43 per share. Analysts are looking for earnings of $6.36 per share for the full year.
Additionally, Express Scripts said that it received two subpoenas in the third quarter.
The first was sent on August 15 from the New York State District Attorney and requested information regarding the company's relationship with drug makers and prescription drug plan clients. The inquiry also asked about the company's payments to and from these groups.
The second was sent on September 12 from the Justice Department and the Massachusetts District Attorney regarding Express Scripts' relationship with pharmaceutical manufacturers, independent charitable foundations and specialty pharmacies.
Express Scripts said that it is cooperating with both requests.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rated this stock as a "buy" with a ratings score of B-.
The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, notable return on equity and compelling growth in net income. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
You can view the full analysis from the report here: ESRX